Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Massive 3,000-Person study tracks hair loss Drug's Real-World safety

NCT ID NCT07152119

Summary

This study is monitoring the safety and effectiveness of Litfulo capsules in real-world patients with severe alopecia areata (patchy hair loss). It will follow 3,000 patients in Korea for up to 48 weeks to track any side effects and measure how much hair regrows. The goal is to understand how the medication performs outside of controlled clinical trials.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE ALOPECIA AREATA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Pfizer, Inc

    RECRUITING

    Seoul, South Korea

Conditions

Explore the condition pages connected to this study.